AAP
SPRY icon

Arax Advisory Partners’s ARS Pharmaceuticals SPRY Stock Holding History

Arax Advisory Partners’s Portfolio SPRY Stock Details SPRY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$2.76K Sell
344
-25
-7% -$240 ﹤0.01% 3008
2025
Q4 		$4.3K Buy
369
+241
+188% +$2.34K ﹤0.01% 2935
2025
Q3 		$1.29K Buy
+128
New +$1.84K ﹤0.01% 3202
2024
Q4 		– Sell
-22
Closed -$319 – 2729
2024
Q3 		$319 Hold
22
– – ﹤0.01% 2465
2024
Q2 		$188 Buy
+22
New +$195 ﹤0.01% 2446

Other funds holding SPRY

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $4.59B AUM 125.28% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $8.16B AUM 68.42% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $915M AUM 209.71% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return